These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11021110)

  • 21. Contrast of the effect of alomide and sodium cromoglycate in the treatment of allergic eye diseases.
    Zhang W; Lin Z
    Yan Ke Xue Bao; 2000 Sep; 16(3):214-6. PubMed ID: 12579651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Alomide, a preventive immunopharmaceutical agent, in the treatment of ocular atopy].
    Krásný J
    Cesk Slov Oftalmol; 1998 Jan; 54(1):41-5. PubMed ID: 9501643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study.
    Fahy GT; Easty DL; Collum LM; Benedict-Smith A; Hillery M; Parsons DG
    Eur J Ophthalmol; 1992; 2(3):144-9. PubMed ID: 1450659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness and impact in the quality of life of ketotifen ophthalmic solution. Results of zeta study in patients with seasonal allergic conjunctivitis].
    Lloves J; Montero Iruzubieta J; Sainz De La Maza Serra MT; Fuster Jensen E; Lladonosa Montull A
    Arch Soc Esp Oftalmol; 2003 Aug; 78(8):433-41. PubMed ID: 12955623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease.
    Sorkin EM; Ward A
    Drugs; 1986 Feb; 31(2):131-48. PubMed ID: 3081317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
    Woerly G; Decot V; Loiseau S; Loyens M; Chihara J; Ono N; Capron M
    Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A systemic approach to the diagnosis and treatment of allergic conjunctivitis].
    Ndoye PA; Ba EA; Wane AM; Sow A; Ndiaye MR; Wade A
    Dakar Med; 2007; 52(1):13-6. PubMed ID: 19102085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative evaluation of the early changes in ocular surface inflammation following MMC-aided papillary resection in severe allergic patients with corneal complications.
    Tanaka M; Dogru M; Takano Y; Miyake-Kashima M; Asano-Kato N; Fukagawa K; Tsubota K; Fujishima H
    Cornea; 2006 Apr; 25(3):281-5. PubMed ID: 16633027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of mast cell-mediated allergic reaction by Amomum xanthiodes.
    Kim SH; Lee S; Kim IK; Kwon TK; Moon JY; Park WH; Shin TY
    Food Chem Toxicol; 2007 Nov; 45(11):2138-44. PubMed ID: 17602813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lodoxamide treatment of allergic conjunctivitis.
    Cerqueti PM; Ricca V; Tosca MA; Buscaglia S; Ciprandi G
    Int Arch Allergy Immunol; 1994 Oct; 105(2):185-9. PubMed ID: 7920019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis.
    Caldwell DR; Verin P; Hartwich-Young R; Meyer SM; Drake MM
    Am J Ophthalmol; 1992 Jun; 113(6):632-7. PubMed ID: 1598953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis.
    Gündüz K; Uçakhan O; Budak K; Eryilmaz T; Ozkan M
    Ophthalmic Res; 1996; 28(2):80-7. PubMed ID: 8792357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: a glimpse of ocular surface in Italian population.
    Lambiase A; Minchiotti S; Leonardi A; Secchi AG; Rolando M; Calabria G; Orsoni J; Zola E; Ferreri G; Aragona P; Reibaldi A; Chisari G; Bonini S
    Ophthalmic Epidemiol; 2009; 16(1):38-41. PubMed ID: 19191180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
    Galatowicz G; Ajayi Y; Stern ME; Calder VL
    Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Allergic ocular diseases; from mechanisms through treatments].
    Fukagawa K
    Arerugi; 2004 Jan; 53(1):8-13. PubMed ID: 14762325
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacological mechanism of topical lodoxamide treatment in vernal keratoconjunctivitis: a flow-cytometric study.
    Avunduk AM; Avunduk MC; Dayanir V; Tekelioğlu Y; Dayioğlu YS
    Ophthalmic Res; 1998; 30(1):37-43. PubMed ID: 9483586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiallergic effects of Vitis amurensis on mast cell-mediated allergy model.
    Kim SH; Kwon TK; Shin TY
    Exp Biol Med (Maywood); 2008 Feb; 233(2):192-9. PubMed ID: 18222974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis.
    Santos CI; Huang AJ; Abelson MB; Foster CS; Friedlaender M; McCulley JP
    Am J Ophthalmol; 1994 Apr; 117(4):488-97. PubMed ID: 8154531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The antiallergic eye drops "polynadyme": development, experimental and clinical studies].
    Maĭchuk IuF; Pozdniakov VI; Pozdniakova VV; Iakushina LN
    Vestn Oftalmol; 2006; 122(5):35-8. PubMed ID: 17087034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical grading of vernal keratoconjunctivitis.
    Bonini S; Sacchetti M; Mantelli F; Lambiase A
    Curr Opin Allergy Clin Immunol; 2007 Oct; 7(5):436-41. PubMed ID: 17873585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.